Effect of prenatal exposure to phenobarbital on the development of monoamine oxidase and glucocorticoids.
1. Fetal exposure to phenobarbital (PB, 30 mg/kg) 2-5 days prior to parturition was conducted in Sprague-Dawley rats. The fetal exposure to PB resulted in: (a) Significant increase (P less than 0.01) in body wt at 23 and 42 days of age; (b) Significant increase (P less than 0.01) in brain wt at all ages studied; (c) Significant decline (P less than 0.05) in liver monoamine oxidase at day 13 of age; (d) Significant (P less than 0.05) increase in plasma corticosterone levels at days 23 and 42.
D000302:Adrenal Cortex / Q000187:drug effects; D000375:Aging; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D003345:Corticosterone / Q000097:blood; D005260:Female; D005938:Glucocorticoids / Q000378:metabolism*; D006128:Growth / Q000187:drug effects; D008099:Liver / Q000201:enzymology; D008995:Monoamine Oxidase / Q000378:metabolism*; D009929:Organ Size / Q000187:drug effects; D010634:Phenobarbital / Q000494:pharmacology*; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D051381:Rats; D011919:Rats, Inbred Strains
D005938:Glucocorticoids; D008995:Monoamine Oxidase; D003345:Corticosterone; D010634:Phenobarbital